title: Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release.
abstract: Rheumatoid arthritis is the most common arthritis and is mainly characterized by symmetric polyarticular joint disorders. Eleutheroside E (EE), a principal active constituent of Acanthopanax senticosus, is reported to have anti-inflammatory effect by inhibiting NF-κB activities. However, the effects of EE on rheumatoid arthritis (RA) severity are largely unknown. The purpose of this study was to indicate whether EE could ameliorate arthritis and reduce inflammatory cytokine release in collagen-induced arthritis (CIA) mice. The results showed that EE attenuated the severity of arthritis by reducing the mean arthritis score and arthritis incidence. EE also significantly decreased the inflammatory cell infiltration, pannus formation, cartilage damage, and bone erosion of CIA mice. Furthermore, EE caused a marked decrease of the production of TNF-α and IL-6 in vivo and in vitro. These observations identify a novel function of EE that results in inhibition of cytokine release, highlighting EE was a potential therapeutic agent for RA.
authors.affiliation: Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: He
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Chen
authors.forename: Chunyang
authors.initials: C
authors.lastname: Zhao
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Qie
authors.forename: Zhaowei
authors.initials: Z
authors.lastname: Yan
authors.forename: Xueming
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D002417:Cattle; D024043:Collagen Type II / Q000633:toxicity*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D005960:Glucosides / Q000494:pharmacology / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000378:metabolism; D017705:Lignans / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D012720:Severity of Illness Index
chemical_list: D024043:Collagen Type II; D016207:Cytokines; D005960:Glucosides; D018836:Inflammation Mediators; D017705:Lignans; C421885:eleutheroside E